NRAS Gene Mutation clinical trials at UCSF
4 in progress, 2 open to eligible people
Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
open to eligible people ages 18-99
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
San Francisco, California and other locations
KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
San Francisco, California and other locations
Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Sorry, in progress, not accepting new patients
This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.
San Francisco, California and other locations
LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Sorry, in progress, not accepting new patients
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
San Francisco, California and other locations
Our lead scientists for NRAS Gene Mutation research studies include Adil Daud.
Last updated: